Antoine Désilets

Featured in: Favicon

nature.com Favicon

aacrjournals.org Favicon

europeanurology.com Favicon

ejcancer.com + 4 more

Articles

Nivolumab in salivary gland cancers: confronting the challenges of unlocking the therapeutic benefits of immunotherapy for rare diseases

Oct 30, 2023 | bmjoncology.bmj.com | Antoine Désilets |Alan Ho

Salivary gland cancers (SGCs) are rare tumours encompassing 24 histological subtypes with diverse biology and variable clinical behaviour, ranging from aggressive to indolent.1 Recurrent and/or metastatic (R/M) SGCs are incurable diseases for which approved drug options are limited to those marketed with tissue agnostic indications (eg, high tumour mutational burden (TMB), NTRK rearrangements, etc).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →